28439713|t|Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival
28439713|a|Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the staging of clinically node-negative breast cancer patients (BCP), demonstrating equivalent survival to ALND while resulting in reduced morbidity. ALND has remained the standard of care for the majority of BCP with clinical axillary metastases or metastases found on SLN biopsy. More recently, it is debated whether ALND could be avoided not only in SLN - negative BCP but also in selected SLN - positive disease or even in all patients. This analysis of pN+ BCP shows the impact of the number of excised lymph nodes on RFS and OAS adjusted by age, tumor size, intrinsic subtypes and adjuvant systemic therapy. In this retrospective, multicenter cohort study, we investigated data from 2992 pN+ primary BCP recruited from 17 participating certified breast cancer centers in Germany between 2001 and 2008 within the BRENDA study group. The median number of excised lymph nodes was 17. The number of excised lymph nodes was neither significant for RFS (p = 0.085) nor for OAS (p = 0.285). Adjustments were made for age, tumor size and intrinsic subtypes. The most important significant parameters for RFS were intrinsic subtypes (p < 0.001) and tumor size (p < 0.001) and for OAS age (p < 0.001) and intrinsic subtypes (p < 0.001). There were no significant differences in RFS and OAS in any subgroup stratified by the number of excised lymph nodes. Only for T3 / T4 tumors, there is a very small significant advantage of ALND for RFS but not for OAS. After adjusting in addition by guideline adherence of adjuvant systemic therapy (AST), intrinsic subtypes and guideline-adherent AST are the most important significant (p < 0.001) parameters for RFS and OAS. The number of excised lymph nodes of pN+ BCP neither correlates with RFS nor with OAS. Survival of pN+ BCP is primarily determined by the biology and the guideline-adherent AST based on the corresponding intrinsic subtypes. These results support the omission of a radical ALND at least for pN+ patients scheduled for breast-conserving surgery (not mastectomy), provided they receive whole breast irradiation and guideline-adherent AST.
28439713	13	32	axillary dissection	T061	C0193867
28439713	48	55	excised	T061	C0728940
28439713	56	67	lymph nodes	T023	C0024204
28439713	71	99	nodal-positive breast cancer	T191	C3160887
28439713	100	108	patients	T101	C1516213
28439713	128	134	impact	T080	C4049986
28439713	138	150	relapse-free	T081	C0242793
28439713	155	171	overall survival	T081	C4086681
28439713	172	191	Sentinel lymph node	T023	C1522495
28439713	193	196	SLN	T023	C1522495
28439713	198	204	biopsy	T060	C0005558
28439713	218	248	axillary lymph node dissection	T061	C0193867
28439713	250	254	ALND	T061	C0193867
28439713	264	271	staging	T185	C0178759
28439713	275	285	clinically	T080	C0205210
28439713	286	313	node-negative breast cancer	T191	C3160889
28439713	314	322	patients	T101	C1516213
28439713	324	327	BCP	T101	C1516213
28439713	367	371	ALND	T061	C0193867
28439713	391	398	reduced	T080	C0392756
28439713	399	408	morbidity	T081	C0026538
28439713	410	414	ALND	T061	C0193867
28439713	469	472	BCP	T101	C1516213
28439713	478	486	clinical	T080	C0205210
28439713	487	506	axillary metastases	T191	C0684830
28439713	510	520	metastases	T191	C0027627
28439713	530	533	SLN	T023	C1522495
28439713	534	540	biopsy	T060	C0005558
28439713	579	583	ALND	T061	C0193867
28439713	613	616	SLN	T023	C1522495
28439713	619	627	negative	T033	C0205160
28439713	628	631	BCP	T101	C1516213
28439713	653	656	SLN	T023	C1522495
28439713	659	667	positive	T033	C1446409
28439713	668	675	disease	T047	C0012634
28439713	691	699	patients	T101	C0030705
28439713	718	725	pN+ BCP	T101	C1516213
28439713	736	742	impact	T080	C4049986
28439713	760	767	excised	T061	C0728940
28439713	768	779	lymph nodes	T023	C0024204
28439713	783	786	RFS	T081	C0242793
28439713	791	794	OAS	T081	C4086681
28439713	807	810	age	T032	C0001779
28439713	812	822	tumor size	T082	C0475440
28439713	824	833	intrinsic	T082	C0205102
28439713	834	842	subtypes	T185	C0449560
28439713	847	872	adjuvant systemic therapy	T061	C0677850
28439713	882	895	retrospective	T080	C1514923
28439713	897	908	multicenter	T062	C1096776
28439713	909	921	cohort study	T081	C0009247
28439713	939	943	data	T078	C1511726
28439713	954	969	pN+ primary BCP	T101	C1516213
28439713	1012	1033	breast cancer centers	T073,T093	C1516604
28439713	1037	1044	Germany	T083	C0017480
28439713	1078	1084	BRENDA	T170	C0021428
28439713	1085	1096	study group	UnknownType	C0681860
28439713	1102	1115	median number	T081	C0876920
28439713	1119	1126	excised	T061	C0728940
28439713	1127	1138	lymph nodes	T023	C0024204
28439713	1161	1168	excised	T061	C0728940
28439713	1169	1180	lymph nodes	T023	C0024204
28439713	1209	1212	RFS	T081	C0242793
28439713	1233	1236	OAS	T081	C4086681
28439713	1276	1279	age	T032	C0001779
28439713	1281	1291	tumor size	T082	C0475440
28439713	1296	1305	intrinsic	T082	C0205102
28439713	1306	1314	subtypes	T185	C0449560
28439713	1362	1365	RFS	T081	C0242793
28439713	1371	1380	intrinsic	T082	C0205102
28439713	1381	1389	subtypes	T185	C0449560
28439713	1406	1416	tumor size	T082	C0475440
28439713	1437	1440	OAS	T081	C4086681
28439713	1441	1444	age	T032	C0001779
28439713	1461	1470	intrinsic	T082	C0205102
28439713	1471	1479	subtypes	T185	C0449560
28439713	1534	1537	RFS	T081	C0242793
28439713	1542	1545	OAS	T081	C4086681
28439713	1590	1597	excised	T061	C0728940
28439713	1598	1609	lymph nodes	T023	C0024204
28439713	1620	1622	T3	T033	C0475374
28439713	1625	1634	T4 tumors	T033	C0475751
28439713	1683	1687	ALND	T061	C0193867
28439713	1692	1695	RFS	T081	C0242793
28439713	1708	1711	OAS	T081	C4086681
28439713	1744	1763	guideline adherence	T064	C0525059
28439713	1767	1792	adjuvant systemic therapy	T061	C0677850
28439713	1794	1797	AST	T061	C0677850
28439713	1800	1809	intrinsic	T082	C0205102
28439713	1810	1818	subtypes	T185	C0449560
28439713	1823	1841	guideline-adherent	T064	C0525059
28439713	1842	1845	AST	T061	C0677850
28439713	1908	1911	RFS	T081	C0242793
28439713	1916	1919	OAS	T081	C4086681
28439713	1935	1942	excised	T061	C0728940
28439713	1943	1954	lymph nodes	T023	C0024204
28439713	1943	1954	lymph nodes	T023	C0024204
28439713	1958	1965	pN+ BCP	T101	C1516213
28439713	1990	1993	RFS	T081	C0242793
28439713	2003	2006	OAS	T081	C4086681
28439713	2020	2027	pN+ BCP	T101	C1516213
28439713	2059	2066	biology	T090	C0678657
28439713	2075	2093	guideline-adherent	T064	C0525059
28439713	2094	2097	AST	T061	C0677850
28439713	2125	2134	intrinsic	T082	C0205102
28439713	2135	2143	subtypes	T185	C0449560
28439713	2171	2179	omission	T033	C3845736
28439713	2185	2192	radical	T080	C0439807
28439713	2193	2197	ALND	T061	C0193867
28439713	2211	2223	pN+ patients	T101	C1516213
28439713	2238	2263	breast-conserving surgery	T061	C0917927
28439713	2269	2279	mastectomy	T061	C0024881
28439713	2304	2328	whole breast irradiation	T061	C3897169
28439713	2333	2351	guideline-adherent	T064	C0525059
28439713	2352	2355	AST	T061	C0677850